Abstract
Significance. Prevalence of diabetes mellitus (DM) is increasing worldwide. People with diabetes are at higher risk to dry eye syndrome (DES). The increasing dependence of society on computers, air conditioning, and visual workload, etc. results in an increase in the manifestations of DES in diabetic patients. A significant part of the socially active population with diabetes requires prescription of drugs aimed at correcting disorders associated with both hyperglycemia and dry eyes. Conservative treatment of DES in case of diabetes includes prescription of artificial tears, metabolic, immunocorrecting, hormonal, antiallergic therapies as well as treatment of meibomian gland dysfunction (MGD). The tear substitutes, however, cannot always satisfy the needs of doctors and patients due to the imperfections of their formulas. Therefore, more and more new drugs are introduced to the market that require a comprehensive assessment.Purpose. To evaluate the clinical efficacy of Keratrop eye drops – a new artificial tear formulation – in dry eye syndrome treatment in patients with diabetes mellitus (DM).Methods. The study included 65 patients (130 eyes) with dry eye syndrome stages I and II associated with mild and moderate diabetes. These were adult patients of both sexes who had not previously received artificial tears as treatment and were undergoing either inpatient or domiciliary care. All studied patients provided a written informed consent and were divided into 2 groups by random sampling. The main group (35 patients) was receiving Keratrop instillations 2 times a day during 14 days, in the course of antidiabetic treatment. Instillations of “artificial tear” were not prescribed to patients of the control group (30 patients), and they only received antidiabetic treatment prescribed by the endocrinologist. Before and after treatment, all patients underwent standard ophthalmic examinations, meibography imaging, tear film assessment and filled in OSDI questionnaires.Results. The study showed that during treatment, in patients of the experimental group – with both I and II dry eye syndrome stages – a significant decrease in subjective and objective manifestations was observed, along with an improvement in the tear film stability. In the control group, positive dynamics was observed only in patients with the first stage of dry eye syndrome.Conclusion. Dry eye syndrome treatment in patients with diabetes should be comprehensive and must include both basic antidiabetic therapy and instillation of tear substitutes.
Highlights
Dry eye syndrome treatment in patients with diabetes should be comprehensive and must include both basic antidiabetic therapy and instillation of tear substitutes
People with diabetes are at higher risk to dry eye syndrome
socially active population with diabetes requires prescription of drugs aimed at correcting disorders associated with
Summary
Оценить клиническую эффективность нового слезозамещающего препарата Кератроп при лечении синдрома сухого глаза у больных сахарным диабетом (СД). В исследование были включены 65 пациентов (130 глаз) с ССГ I и II степени на фоне СД легкой или средней степени тяжести, ранее не получавшие препараты «искусственной слезы», находившиеся на стационарном и/или амбулаторном лечении; обоих полов; в возрасте старше 18 лет; давшие письменное информированное согласие на участие в исследовании. В контрольной группе (30 пациентов) препараты «искусственной слезы» не закапывали, получали лишь гипогликемическую терапию, назначенную эндокринологом. Исследование показало, что у пациентов основной группы в процессе лечения наблюдали достоверное снижение субъективных и объективных проявлений наряду с улучшением стабильности слезной пленки при синдроме сухого глаза I и II степени. Терапия пациентов с синдромом сухого глаза при сахарном диабете должна быть комплексной, включающей как базовую гипогликемическую терапию, так и инстилляции слезозаменителей. Эффективность препарата Кератроп при лечении синдрома сухого глаза у пациентов с сахарным диабетом. Nabieva Tashkent medical academy, 2, Faroby Str., Tashkent, 100109, Uzbekistan 2 Endocrinology Medical Center, 56, Prospekt Mirzo Ulugbeka, Tashkent, 100056, Uzbekistan
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
